Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal

Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been c...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2002-05, Vol.4 (3), p.169-172
Main Authors: Guthrie, Robert, Reeves, Richard A.
Format: Article
Language:English
Subjects:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Blood Pressure Determination
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Hypertension - diagnosis
Hypertension - drug therapy
Male
Middle Aged
Original Papers
Pyridines - administration & dosage
Reference Values
Severity of Illness Index
Thiazepines - administration & dosage
Time Factors
Treatment Outcome
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623
cites cdi_FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623
container_end_page 172
container_issue 3
container_start_page 169
container_title The journal of clinical hypertension (Greenwich, Conn.)
container_volume 4
creator Guthrie, Robert
Reeves, Richard A.
description Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been controlled (seated diastolic blood pressure
doi_str_mv 10.1111/j.1524-6175.2002.01400.x
format article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8101813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JCH1400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623</originalsourceid><addsrcrecordid>eNqNkE1OwzAQhS0EoqVwBeQLJIzjOEmRQEIRUFClIhTE0nISp3WVxJET-sOKI3BGTkLSlr8ds5mR57031ocQJmCTts7mNmGOa3nEZ7YD4NhAXAB7tYf67ROxfOJ7--38Jeqho7qeAzBKh3CIesQBl1GP9VE6KUQlGqNy0eAHoxcqlTUe63L68fYeSVPgUJeN0TnWGR6tK2kaWdZKl-f4Cj-KMtWFepUpjowSG01kpGgKWTb4WTWz1IilyI_RQSbyWp7s-gA93VxH4cgaT27vwquxldCAgUWSeBhnKXE8PyCU0lgGiUhcFgODTPpto65H4swlbuCIbJi6VIIPviM9CBLPoQN0uc2tXuJCpkn7CyNyXhlVCLPmWij-d1OqGZ_qBQ8IkO7kAAXbgMToujYy-_YS4B15PucdVN5B5R15viHPV6319PftH-MOdSu42AqWKpfrfwfz-3DUTfQTNB6Upg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal</title><source>PubMed Central</source><creator>Guthrie, Robert ; Reeves, Richard A.</creator><creatorcontrib>Guthrie, Robert ; Reeves, Richard A.</creatorcontrib><description>Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been controlled (seated diastolic blood pressure &lt;90 mm Hg) on omapatrilat for at least 6 months, with or without adjunctive antihypertensive medications. This double‐blind study randomized 83 patients to receive either their established omapatrilat dose or placebo for 8 weeks; any concomitant antihypertensive medications were kept constant. Patients continuing on omapatrilat had no change in blood pressure. Patients whose chronic omapatrilat treatment was replaced by placebo had clinically important increases in both systolic (+16.5 mm Hg) and diastolic (+9.6 mm Hg) blood pressures (both p&lt;0.001). An increase in blood pressure was also seen in patients who were taking adjunctive antihypertensive medications prior to withdrawal of omapatrilat. This study demonstrates that when compared to withdrawal placebo, omapatrilat maintains clinically and statistically significant blood pressure reductions.</description><identifier>ISSN: 1524-6175</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/j.1524-6175.2002.01400.x</identifier><identifier>PMID: 12045365</identifier><language>eng</language><publisher>Three Parklands Drive, Darien, CT 06820‐3652: Le Jacq Communications, Inc</publisher><subject>Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors - administration &amp; dosage ; Blood Pressure Determination ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Hypertension - diagnosis ; Hypertension - drug therapy ; Male ; Middle Aged ; Original Papers ; Pyridines - administration &amp; dosage ; Reference Values ; Severity of Illness Index ; Thiazepines - administration &amp; dosage ; Time Factors ; Treatment Outcome ; Withholding Treatment</subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2002-05, Vol.4 (3), p.169-172</ispartof><rights>Copyright 2002 Le Jacq</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623</citedby><cites>FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101813/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101813/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12045365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guthrie, Robert</creatorcontrib><creatorcontrib>Reeves, Richard A.</creatorcontrib><title>Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been controlled (seated diastolic blood pressure &lt;90 mm Hg) on omapatrilat for at least 6 months, with or without adjunctive antihypertensive medications. This double‐blind study randomized 83 patients to receive either their established omapatrilat dose or placebo for 8 weeks; any concomitant antihypertensive medications were kept constant. Patients continuing on omapatrilat had no change in blood pressure. Patients whose chronic omapatrilat treatment was replaced by placebo had clinically important increases in both systolic (+16.5 mm Hg) and diastolic (+9.6 mm Hg) blood pressures (both p&lt;0.001). An increase in blood pressure was also seen in patients who were taking adjunctive antihypertensive medications prior to withdrawal of omapatrilat. This study demonstrates that when compared to withdrawal placebo, omapatrilat maintains clinically and statistically significant blood pressure reductions.</description><subject>Adult</subject><subject>Aged</subject><subject>Angiotensin-Converting Enzyme Inhibitors - administration &amp; dosage</subject><subject>Blood Pressure Determination</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Papers</subject><subject>Pyridines - administration &amp; dosage</subject><subject>Reference Values</subject><subject>Severity of Illness Index</subject><subject>Thiazepines - administration &amp; dosage</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Withholding Treatment</subject><issn>1524-6175</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqNkE1OwzAQhS0EoqVwBeQLJIzjOEmRQEIRUFClIhTE0nISp3WVxJET-sOKI3BGTkLSlr8ds5mR57031ocQJmCTts7mNmGOa3nEZ7YD4NhAXAB7tYf67ROxfOJ7--38Jeqho7qeAzBKh3CIesQBl1GP9VE6KUQlGqNy0eAHoxcqlTUe63L68fYeSVPgUJeN0TnWGR6tK2kaWdZKl-f4Cj-KMtWFepUpjowSG01kpGgKWTb4WTWz1IilyI_RQSbyWp7s-gA93VxH4cgaT27vwquxldCAgUWSeBhnKXE8PyCU0lgGiUhcFgODTPpto65H4swlbuCIbJi6VIIPviM9CBLPoQN0uc2tXuJCpkn7CyNyXhlVCLPmWij-d1OqGZ_qBQ8IkO7kAAXbgMToujYy-_YS4B15PucdVN5B5R15viHPV6319PftH-MOdSu42AqWKpfrfwfz-3DUTfQTNB6Upg</recordid><startdate>200205</startdate><enddate>200205</enddate><creator>Guthrie, Robert</creator><creator>Reeves, Richard A.</creator><general>Le Jacq Communications, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>200205</creationdate><title>Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal</title><author>Guthrie, Robert ; Reeves, Richard A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Angiotensin-Converting Enzyme Inhibitors - administration &amp; dosage</topic><topic>Blood Pressure Determination</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Papers</topic><topic>Pyridines - administration &amp; dosage</topic><topic>Reference Values</topic><topic>Severity of Illness Index</topic><topic>Thiazepines - administration &amp; dosage</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guthrie, Robert</creatorcontrib><creatorcontrib>Reeves, Richard A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guthrie, Robert</au><au>Reeves, Richard A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2002-05</date><risdate>2002</risdate><volume>4</volume><issue>3</issue><spage>169</spage><epage>172</epage><pages>169-172</pages><issn>1524-6175</issn><eissn>1751-7176</eissn><abstract>Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin‐converting enzyme, increasing levels of vasodilatory peptides while decreasing production of angiotensin II. This study evaluated the clinical effects of withdrawal of omapatrilat after a patient's hypertension had been controlled (seated diastolic blood pressure &lt;90 mm Hg) on omapatrilat for at least 6 months, with or without adjunctive antihypertensive medications. This double‐blind study randomized 83 patients to receive either their established omapatrilat dose or placebo for 8 weeks; any concomitant antihypertensive medications were kept constant. Patients continuing on omapatrilat had no change in blood pressure. Patients whose chronic omapatrilat treatment was replaced by placebo had clinically important increases in both systolic (+16.5 mm Hg) and diastolic (+9.6 mm Hg) blood pressures (both p&lt;0.001). An increase in blood pressure was also seen in patients who were taking adjunctive antihypertensive medications prior to withdrawal of omapatrilat. This study demonstrates that when compared to withdrawal placebo, omapatrilat maintains clinically and statistically significant blood pressure reductions.</abstract><cop>Three Parklands Drive, Darien, CT 06820‐3652</cop><pub>Le Jacq Communications, Inc</pub><pmid>12045365</pmid><doi>10.1111/j.1524-6175.2002.01400.x</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1524-6175
ispartof The journal of clinical hypertension (Greenwich, Conn.), 2002-05, Vol.4 (3), p.169-172
issn 1524-6175
1751-7176
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8101813
source PubMed Central
subjects Adult
Aged
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Blood Pressure Determination
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Hypertension - diagnosis
Hypertension - drug therapy
Male
Middle Aged
Original Papers
Pyridines - administration & dosage
Reference Values
Severity of Illness Index
Thiazepines - administration & dosage
Time Factors
Treatment Outcome
Withholding Treatment
title Omapatrilat Provides Long‐Term Control of Hypertension: A Randomized Trial of Treatment Withdrawal
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A49%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Omapatrilat%20Provides%20Long%E2%80%90Term%20Control%20of%20Hypertension:%20A%20Randomized%20Trial%20of%20Treatment%20Withdrawal&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Guthrie,%20Robert&rft.date=2002-05&rft.volume=4&rft.issue=3&rft.spage=169&rft.epage=172&rft.pages=169-172&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/j.1524-6175.2002.01400.x&rft_dat=%3Cwiley_pubme%3EJCH1400%3C/wiley_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3850-1cb9bfd126781333be8cac45b050fe7b053461bf41482af9d43e07072e608c623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/12045365&rfr_iscdi=true